Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biohit Oyj Board/Management Information 2021

May 24, 2021

3304_rns_2021-05-24_bbc9654b-b98c-4a17-937c-cc08c1ffc4bc.html

Board/Management Information

Open in viewer

Opens in your device viewer

Changes to Biohit Oyj’s management

Changes to Biohit Oyj’s management

Stock exchange release Biohit Oyj

24th May 2021 at 01.30 pm local time (EEST)

Master of Social Sciences Jussi Hahtela (b. 1973) has been appointed Chief
Financial Officer and as a member of the Management Team of Biohit Oyj starting
June 4th 2021. He will also be responsible for HR function and IT function.
Hahtela will report to deputy CEO Osmo Suovaniemi. Hahtela has previously worked
in Nordea for example as chief strategist and Head of FX sales Finland.

Additional information:

Chairman of the Board Osmo Suovaniemi, Biohit Oyj

tel. +358 9 773 861

[email protected]

www.biohithealthcare.com

Biohit Oyj in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s
mission ‘Innovating for Health’ means that we provide innovative products and
services to promote research and early diagnostics. Biohit is headquartered in
Helsinki and has subsidiaries in Italy and the UK. Biohit’s B series shares
(BIOBV) are quoted on NASDAQ OMX Helsinki under Small cap/Healthcare.
www.biohithealthcare.com